Radioimmunotherapy Versus Autologous Hematopoietic Stem Cell Transplantation in Relapse/Refractory Follicular Lymphoma: A Fondazione Italiana Linfomi Multicenter, Randomized, Phase III Trial

Patients age 18–65 years with relapsed/refractory ollicular lymphoma and without significant comorbidities were enrolled and treated with three courses of conventional, investigator-chosen chemoimmunotherapies.